Celecoxib

證據等級: L5

預測適應症: 10 個

Celecoxib: From Inflammatory Arthritis to Inflammatory Spondylopathy

Research Use Only. This report is intended for research and evaluation purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All prescribing decisions must be made by qualified healthcare professionals in accordance with current UK guidelines.

One-Sentence Summary

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used in clinical practice for the symptomatic treatment of osteoarthritis and rheumatoid arthritis. The TxGNN model predicts it may be effective for inflammatory spondylopathy (encompassing ankylosing spondylitis and axial spondyloarthritis), with 19 clinical trials and 20 publications currently supporting this direction. This is the highest-evidence prediction identified in a multi-indication screening (10 candidates evaluated), achieving Evidence Level L1 — the strongest possible rating.

Note on report scope: This evidence pack evaluated 10 predicted indications simultaneously. The report focuses on rank 9 — inflammatory spondylopathy as the primary indication, as it carries the highest evidence level (L1) and the only actionable recommendation (“Proceed with Guardrails”) in this dataset. The remaining nine predictions are all rated L4–L5 with a “Hold” recommendation and are not detailed further here.

Quick Overview

Item	Content
Original Indication	Not mapped in current data — Celecoxib is a COX-2-selective NSAID; verify current approved indications via MHRA/emc
Predicted New Indication	Inflammatory Spondylopathy (incl. Ankylosing Spondylitis, Axial Spondyloarthritis)
TxGNN Prediction Score	99.80% (Global rank: 2,564)
Evidence Level	L1
UK Market Status	Not mapped in current dataset — see regulatory note below
Number of Marketing Authorisations	Not mapped in current dataset — see regulatory note below
Recommended Decision	Proceed with Guardrails

Regulatory data note: The UK marketing authorisation fields in this evidence pack returned no records for Celecoxib (market status listed as not marketed; 0 licences). This is almost certainly a pipeline data collection issue rather than a reflection of actual market status. Clinicians should verify directly via the electronic Medicines Compendium (emc) at medicines.org.uk or the MHRA Products website. Celecoxib (Celebrex®, 100 mg and 200 mg capsules) is known to hold MHRA marketing authorisation for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults; the BNF classifies it under Section 10.1.1 (Non-steroidal anti-inflammatory drugs). The UK regulatory data pipeline for this drug should be reviewed and corrected.

Why Is This Prediction Reasonable?

Celecoxib works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, blocking the synthesis of prostaglandin E2 (PGE2) and related pro-inflammatory mediators. Its selectivity for COX-2 over COX-1 accounts for its more favourable gastrointestinal safety profile compared to non-selective NSAIDs. Detailed mechanism of action data was not returned by the DrugBank query in this evidence pack (data gap DG002); however, Celecoxib’s pharmacology is extensively characterised in the clinical literature, including multiple studies within this evidence pack, and its mechanism is well understood in inflammatory musculoskeletal disease.

In inflammatory spondylopathy — encompassing ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and related subtypes — COX-2 is highly expressed in inflamed spinal ligaments, entheses, and sacroiliac joints. Selective inhibition of COX-2 by Celecoxib directly reduces the local PGE2-driven inflammatory cycle responsible for the pain, morning stiffness, and progressive ankylosis that define these conditions. The mechanistic rationale is therefore direct and robust, explaining why multiple Phase 3 RCTs have already confirmed clinical benefit.

A particularly compelling finding is reported in a 2025 study (PMID 39757202), which proposes that Celecoxib may be the only NSAID capable of inhibiting radiographic bone progression in spondyloarthritis — potentially via modulation of the Wnt/BMP signalling pathway independently of COX inhibition per se. If confirmed, this would give Celecoxib a genuine disease-modifying role in inflammatory spondylopathy beyond symptom control, further strengthening this TxGNN prediction. The breadth and consistency of the clinical evidence base — spanning Phase 3 RCTs, large Phase 4 studies, national cohorts, and systematic reviews — makes this one of the most robustly supported drug–indication predictions possible from a repurposing analysis.

Clinical Trial Evidence

Trial	Phase	Status	Enrolment	Key Findings
NCT00648141	Phase 3	Completed	458	12-week comparison of Celecoxib 200 mg once daily, 200 mg twice daily, and diclofenac 75 mg SR twice daily in AS; primary confirmatory trial of Celecoxib’s symptomatic efficacy and safety in AS
NCT00762463	Phase 3	Completed	240	Celecoxib 200 mg once daily vs diclofenac 75 mg SR once daily in Chinese patients with AS (6-week RCT + 6-week extension at 400 mg); broadens generalisability of Phase 3 evidence to non-Western populations
NCT02758782	Phase 4	Completed	156	CONSUL trial: Celecoxib added to golimumab (TNF inhibitor) vs golimumab monotherapy over 2 years in radiographic axial SpA; assesses whether continuous NSAID use retards structural spinal damage progression
NCT02528201	Phase 4	Completed	330	Celecoxib 200 mg once daily vs 400 mg once daily vs diclofenac three times daily in AS over 12 weeks; 12-week confirmatory study extending the results of a prior 6-week Phase 3 trial
NCT01934933	Phase 4	Completed	150	Multi-centre open-label RCT: etanercept 50 mg weekly vs Celecoxib 200 mg twice daily vs combination over 54 weeks in active AS; primary endpoint is MRI SPARCC score of sacroiliac joints
NCT02456363	Phase 2	Unknown	300	Registry study: adalimumab with NSAIDs vs adalimumab alone in AS; provides real-world data on Celecoxib use patterns in combination with biologic therapy
NCT02355236	Phase 4	Unknown	106	Double-blind active-controlled RCT: Naxozol (naproxen + esomeprazole) vs Celecoxib in OA/RA/AS; compares gastroprotective effect and pain relief between the two approaches
NCT05164198	Phase 4	Unknown	448	Multi-centre prospective RCT: standard-dose vs reduced-dose TNF inhibitor in stable AS; NSAIDs including Celecoxib used as background therapy
NCT04115098	Phase 2	Terminated	42	N-of-1 trial series comparing selective COX-2 inhibitors vs non-selective NSAIDs in axial SpA; terminated early but provides proteomic biomarker and individualised response data
NCT01709656	N/A	Completed	120	Prospective open-label trial: human mesenchymal stem cells vs NSAIDs (NSAID arm includes Celecoxib) in active AS; provides mechanistic and gene expression profiling data on disease pathophysiology

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39757202	2025	Systematic Review	BMB Reports	Celecoxib is the only NSAID shown to inhibit radiographic bone progression in spondyloarthritis; proposed COX-2–independent mechanism involves modulation of bone formation pathways, potentially Wnt/BMP signalling
40028763	2025	Comparative Cohort	Scandinavian Journal of Rheumatology	Nationwide retrospective cohort in AS: cardiovascular disease and GI bleeding risk is comparable between Celecoxib and non-selective NSAIDs, supporting Celecoxib as a viable long-term option
40911151	2025	Umbrella Review	Drugs	Systematic synthesis of meta-analyses reporting on Celecoxib safety in chronic musculoskeletal disorders; provides the most comprehensive current safety signal assessment for this drug class
38228361	2024	RCT	Annals of the Rheumatic Diseases	CONSUL trial report: Celecoxib added to golimumab did not significantly reduce radiographic spinal progression vs golimumab alone at 2 years in r-axSpA, though exploratory findings support disease activity benefits
38832489	2024	RCT	Scandinavian Journal of Rheumatology	Randomised, double-blind, placebo-controlled trial of iguratimod combined with Celecoxib in active axSpA; assesses combination therapy efficacy and safety
36800138	2023	RCT	Clinical Rheumatology	Celecoxib vs imrecoxib in axSpA: analyses changes in bone metabolism markers and angiogenesis related to sacroiliac joint inflammation, linking treatment response to mechanistic biomarkers
28626213	2017	RCT	Medical Science Monitor	Randomised trial (n=51 completers) of imrecoxib vs Celecoxib 200 mg twice daily in axSpA; MRI SPARCC scores and serum DKK-1 levels used to correlate imaging and clinical response
25623277	2015	Population Cohort	Arthritis Care & Research	Swedish national cohort: comparative rates of GI, renovascular, and cardiovascular adverse events for etoricoxib, Celecoxib, and non-selective NSAIDs specifically in AS/SpA patients — key long-term safety reference
22141388	2011	Systematic Review	Drugs	Comprehensive systematic review of Celecoxib efficacy and tolerability in OA, RA, and AS; summarises the clinical evidence base that supports current MHRA-approved indications
16960941	2006	Clinical Study	Journal of Rheumatology	Evaluates efficacy and safety of Celecoxib in patients with AS; an early foundational study demonstrating significant clinical benefit that supported original AS indication approval

UK Market Information

Current data in this evidence pack contains no marketing authorisation records for Celecoxib in the United Kingdom. This is a known pipeline data collection gap (see metadata DG001) and does not reflect the actual regulatory status of this drug.

Clinicians should consult the following authoritative UK sources directly:

Electronic Medicines Compendium (emc): medicines.org.uk — search “Celebrex” for full SmPC
MHRA Products: products.mhra.gov.uk — marketing authorisation records
BNF Online: bnf.nice.org.uk — Section 10.1.1 for Celecoxib prescribing guidance
NICE Guidance: NG65 — Spondyloarthritis in over 16s: diagnosis and management

Action required for the UK TxGNN data pipeline: The MHRA authorisation matching process for Celecoxib (Celebrex®) should be reviewed and corrected. The drug holds a valid UK marketing authorisation and should appear in future evidence packs with complete licence and approved indication data.

Safety Considerations

Specific UK SmPC safety data — including formalised warnings, contraindications, and drug interaction data — is not available in this evidence pack (pipeline data gap DG001; DDI query returned no results).

Please refer to the Celebrex® SmPC (available on emc) and BNF Section 10.1.1 for full prescribing information, contraindications, and monitoring requirements before any clinical use. Report suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

The literature evidence within this pack highlights several safety considerations specifically relevant to Celecoxib use in inflammatory spondylopathy:

Cardiovascular risk: A 2025 nationwide cohort study (PMID 40028763) and a Swedish national registry (PMID 25623277) both examined cardiovascular and GI outcomes with Celecoxib in AS/SpA patients — these should be reviewed alongside the SmPC cardiovascular warnings
Long-term renal and hepatic monitoring: A 2024 prospective cohort study (PMID 39315555) assessed liver and kidney function in AS patients on long-term continuous NSAIDs; monitoring guidance is available therein
Concomitant methotrexate: A Cochrane review (PMID 22071858) specifically assessed NSAID safety in patients receiving methotrexate for inflammatory arthritis; consult before co-prescribing
Comprehensive safety synthesis: A 2025 umbrella review (PMID 40911151) systematically synthesises safety evidence across meta-analyses of Celecoxib in chronic musculoskeletal conditions and is the most current overall safety reference

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs (including NCT00648141, n=458 and NCT00762463, n=240) directly confirm Celecoxib’s efficacy in ankylosing spondylitis — a core subtype of inflammatory spondylopathy — and emerging 2025 systematic evidence (PMID 39757202) suggests Celecoxib may uniquely inhibit radiographic bone progression in spondyloarthritis beyond symptom control, potentially representing a meaningful disease-modifying advantage over other NSAIDs.

To proceed, the following is needed:

Regulatory pipeline fix (priority): Update the UK MHRA data collection pipeline to correctly capture Celecoxib’s existing marketing authorisation; confirm whether an additional label extension to non-radiographic axial SpA (nr-axSpA) would be clinically and commercially warranted
SmPC and contraindication data (DG001 — Blocking): Retrieve full SmPC warnings and contraindications text to complete the S1 safety screening step; this is currently a blocking data gap
Drug interaction data: Re-run a targeted DDI query (the current query returned 0 results, which is implausible for a widely prescribed NSAID); prioritise interactions with TNF inhibitors, methotrexate, aspirin, and anticoagulants relevant to the spondyloarthritis patient population
MOA data confirmation (DG002): Obtain complete DrugBank mechanism of action data to formally characterise the proposed Wnt/BMP pathway interaction and support any future label extension submission or NICE appraisal
NICE NG65 alignment: Map Celecoxib’s evidence base against the current NICE axial spondyloarthritis guideline (NG65) to confirm its positioning in the UK treatment pathway and identify whether a technology appraisal update is appropriate
Paediatric population: Consider a separate evaluation for RF-positive polyarticular juvenile idiopathic arthritis (JIA; prediction rank 8 in this pack, Evidence Level L4), given historical FDA paediatric JIA supplemental data referenced in the evidence; this may represent a viable extension route through the MHRA’s paediatric investigation plan process
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.